CA-LASERFICHE
15.5.2024 16:01:35 CEST | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — announced today that CRN®, a brand of The Channel Company, has named Noel Loughrin, Katherine Hou, and Kristen Petruzzelli to the Women of the Channel list for 2024.
These channel leaders are an instrumental part of Laserfiche’s success, which includes growing the Laserfiche channel’s footprint and expertise in various industries. Loughrin, Hou, and Petruzzelli are committed to providing the resources and support that enable solution providers to drive digital transformation at organizations around the world.
As senior strategic solutions manager for the public sector, Loughrin is a passionate technologist and Laserfiche advocate. Loughrin works with organizations in local, state, and federal governments, as well as education, to bring about transformative change for constituents, students, and staff. She puts her public sector expertise at the service of Laserfiche channel partners by fostering strategic technology partnerships and championing integrations that build awareness, generate opportunities, and encourage customer retention.
Hou is a territory manager and trusted resource and advocate for Laserfiche channel partners. She focuses on strategic campaigns that empower partners and amplify the Laserfiche brand. Hou is committed to building awareness at industry events, cultivating trust between Laserfiche and its channel partners, and serving as a reliable resource during rapidly changing socio-economic conditions.
As senior customer success manager, Petruzzelli is dedicated to elevating the level of Laserfiche customer service and streamlining operational processes. She recently optimized service standards by spearheading new policies and procedures to save time for customers and solution providers, as well as increase customer satisfaction.
Every year, CRN highlights women from vendor, distributor, and solution provider organizations whose vision and leadership have a beneficial influence on the technology industry. The CRN 2024 Women of the Channel honorees are creative, strategic leaders who show ongoing commitment to using their skills to innovate and drive success for their partners and customers.
With this recognition, CRN honors these women leaders for their unwavering dedication and commitment to furthering channel excellence.
“It is a great privilege to honor the remarkable achievements of these women leaders in the IT channel,” said Jennifer Follett, VP, U.S. Content and Executive Editor, CRN at The Channel Company. “Each woman on the list has demonstrated a deep commitment to innovation and leadership that advances their organizations and drives transformation and success across the IT channel.”
“In the past year these leaders have worked purposefully in not only growing our channel presence but also in empowering resellers, creating a customer-centric partner ecosystem that encourages and enables our solution providers to grow with Laserfiche,” said Vicki VanValin, vice president of sales at Laserfiche. “This recognition from CRN underscores our dedication to the Laserfiche Solution Provider Program, which is essential to Laserfiche's growth and delivering on our vision.”
The 2024 Women of the Channel list will be featured in the June issue of CRN Magazine, with online coverage starting May 13 at www.CRN.com/WOTC.
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management, and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare, and manufacturing — use Laserfiche to boost productivity, scale their business, and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter | LinkedIn | Facebook
About The Channel Company
The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers, and end-users. Backed by over 40 years of unequaled channel experience, we draw from our deep knowledge to envision innovative solutions for ever-evolving challenges in the technology marketplace. www.thechannelcompany.com
Follow The Channel Company: X and LinkedIn
© 2024. CRN is a registered trademark of The Channel Company, Inc. All rights reserved.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240515678202/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom